| Bioactivity | INF4E is a potent NLRP3 inflammasome inhibitor. INF4E inhibits caspase-1 and NLRP3 ATPase activities. INF4E shows protection against the IR-induced myocardial injury and dysfunction[1][2]. | ||||||||||||
| Invitro | INF4E (compound 9) preventes both ATP- and nigericin-triggered pyroptosis of human THP-1 cells in a time- and concentration-dependent manner[3]. | ||||||||||||
| In Vivo | INF4E significantly reduces the in infarct size and lactate dehydrogenase release and improvement in postischemic left ventricular pressure[1].INF4E attenuates the formation of NLRP3 inflammasome complex was induced by myocardial IR (ischemia/reperfusion) in a time-dependent way[1]. | ||||||||||||
| Name | INF4E | ||||||||||||
| CAS | 88039-46-7 | ||||||||||||
| Formula | C12H13ClO3 | ||||||||||||
| Molar Mass | 240.68 | ||||||||||||
| Appearance | Liquid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Shi Y, et al. NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages. Int Immunopharmacol. 2021 Mar;92:107358. [2]. Mezzaroma E,et al. NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases. Molecules. 2021 Feb 12;26(4):976. [3]. occo M, et al. Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis. J Med Chem. 2014 Dec 26;57(24):10366-82. |